Korean AI drug developer secures $14m Series B
Oncocross, a South Korean drug developer that uses artificial intelligence (AI) to identify new applications for treatments already in clinical trials, has raised KRW16.5 billion ($14 million) in Series B funding led by Smilegate Investment and GNTech Venture Capital.
The company is now in discussions with domestic and Chinese strategic investors regarding partnerships and additional investments prior to a KRW10-20 billion pre-IPO round, CEO Kim Yi-rang told Mergermarket....
More on North Asia
Latest News
FountainVest poised for first close on latest China fund
FountainVest Partners has set a target of $2.8 billion for its fourth China-focused fund, with a first close of more than $1 billion expected as soon as this week.
CPE leads $224m round for China cancer diagnostics business
3D Diagnostic, a diagnostics spinout from Chinese tumor immunotherapy specialist 3D Medicines, has raised RMB1.5 billion ($224 million) in funding led by CPE, formerly known as CITIC Private Equity.
OTPP leads $360m round for Asia data center business
Ontario Teachers’ Pension Plan (OTPP) has led a $360 million equity investment in Singapore-based data center developer Princeton Digital Group (PDG).
Australia's V2Food raises $55m Series B
Australian alternative protein producer V2Food has raised a A$77 million ($55 million) Series B round featuring Sequoia Capital China and Temasek Holdings.